Mallinckrodt closes $185 million deal

Mallinckrodt has wrapped up its sale of its hemostasis products to Baxter International Inc. The deal, which has a value of about $185 million, includes a base payment of $153 million and further potential milestone payments in the future. Baxter acquired Mallinckrodt's Preveleak and Recothrom Thrombin topical products, which are both used to control bleeding during surgery, as well as t he manufacturing operation for Preveleak. "This action further illustrates the strategic evolution of our portfolio,…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news